Related Experiment Videos
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents
1Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond, VA 23298, USA.
Current Oncology Reports
|January 31, 2004
Summary
Cyclin-dependent kinase (CDK) inhibitors show promise as anticancer drugs. Combining CDK inhibitors with other therapies can enhance antitumor effects and apoptosis, supporting new clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) and related pathways are key targets for anticancer drug development.
- Several CDK inhibitors, including flavopiridol, UCN-01, CYC202, and BMS-387032, have demonstrated preclinical antitumor activity and are in clinical trials.
Purpose of the Study:
- To review the mechanisms of action of select CDK inhibitors.
- To explore the potential of combination therapies involving CDK inhibitors for cancer treatment.
Main Methods:
- Review of preclinical and clinical data on flavopiridol, UCN-01, CYC202, and BMS-387032.
- Analysis of the molecular effects of CDK inhibitors on tumor cells, including transcriptional inhibition, apoptosis induction, and cell cycle regulation.
- Evaluation of combination strategies with cytotoxic agents and signal transduction inhibitors.
Main Results:
- Flavopiridol inhibits multiple CDKs, disrupts P-TEFb, induces apoptosis, and exhibits antiangiogenic effects.
- UCN-01 exhibits antitumor effects via CDK inhibition, cdc2/CDK1 activation, and apoptosis induction, independent of protein kinase C (PKC).
- Combination of CDK inhibitors with other agents significantly enhances antitumor activity and apoptosis in preclinical models.
Conclusions:
- CDK inhibitors represent a promising class of anticancer therapeutics.
- Combination regimens involving CDK inhibitors show potential for enhanced efficacy and warrant clinical investigation.